Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Becton Dickinson Discontinuing Glucose Monitor Development Program

This article was originally published in The Gray Sheet

Executive Summary

Becton Dickinson's decision not to introduce a stand-alone blood glucose monitoring product by year-end gives the company extra resources to focus further on its "strategic bullseye" represented by sharps protection, biosciences and insulin delivery.

You may also be interested in...



Becton Dickinson Signs Sharps Agreement But Predicts Disappointing Quarter

Becton Dickinson's safety engineered "sharps" program with Kaiser Permanente, announced June 16, signals the initial success of a strategy that is expected to carry the company out of its recent warnings of slower growth.

Federal Safe Needle Bill Mandates Use Of Sharps With Protective Features

Legislation introduced in the House May 20 by Reps. Pete Stark (D-Calif.) and Marge Roukema (R-N.J.) would amend the Occupational Safety and Health Administration's bloodborne pathogen standard to require that employers use needleless systems and sharps with engineered safety features to reduce the risk of accidental needlesticks among health care workers.

HHS Policy Move Means FDA Must Publish More Documentation To Support Rulemaking Decisions

To be more transparent and allow more public discourse, the HHS now requires all its agencies to publish documents it uses to rationalize proposed rules and demonstration projects.

UsernamePublicRestriction

Register

OM006145

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel